Farxiga (Dapagliflozin) for Heart Failure with Reduced Ejection Fraction
Yes, Farxiga 10 mg once daily is strongly recommended for patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status, as it reduces cardiovascular death and heart failure hospitalizations. 1
Who Should Receive Farxiga
Eligible Patients
- LVEF ≤40% (some guidelines extend to LVEF <45%) 1, 2
- NYHA class II-IV symptoms 3, 1
- eGFR ≥25 mL/min/1.73 m² for heart failure indication 3, 4
- Systolic blood pressure ≥100 mm Hg (stable) 2
- With or without type 2 diabetes - the benefit is consistent regardless 1
Dosing
- 10 mg once daily for heart failure indication 3, 5, 4
- No titration needed - start at target dose 4
- Can be initiated on top of existing guideline-directed medical therapy (ACE inhibitors/ARBs/ARNI, beta-blockers, mineralocorticoid receptor antagonists) 1
Key Contraindications and Cautions
Absolute Contraindications
- Type 1 diabetes (increased ketoacidosis risk) 6, 4
- On dialysis 3, 6, 4
- Known hypersensitivity to dapagliflozin 4
Relative Contraindications/Cautions
- eGFR <25 mL/min/1.73 m²: Do not initiate, but may continue if already on therapy 3, 4
- Volume depletion: Correct before starting 6, 4
- Systolic BP <100 mm Hg: Higher risk of hypotension 2
Clinical Benefits
The evidence is robust from the DAPA-HF trial 1, 7, 8:
- 26% reduction in cardiovascular death or worsening heart failure (HR 0.74,95% CI 0.65-0.85)
- 30% reduction in heart failure hospitalizations (HR 0.70,95% CI 0.59-0.83)
- 18% reduction in cardiovascular death (HR 0.82,95% CI 0.69-0.98)
- Benefits appear within 30 days of initiation 1
- Improves quality of life and LVEF 1, 9, 10
Important Safety Considerations
Common Adverse Effects
- Genital mycotic infections (10-15% in women, lower in men) - usually manageable with antifungals, rarely require discontinuation 1
- Temporary eGFR decline (up to 15%) - typically resolves within 1-3 months 1
- Volume depletion/hypotension - especially in elderly or those on high-dose diuretics 1, 6
Rare but Serious
- Diabetic ketoacidosis (0.1% incidence) - can occur with normal glucose levels (<250 mg/dL) 1, 6, 4
- Fournier's gangrene (necrotizing fasciitis of perineum) - extremely rare but life-threatening 6
- Acute kidney injury - monitor in setting of volume depletion 1, 6
Practical Implementation
Monitoring
- Baseline: eGFR, potassium, volume status, blood pressure 4
- Follow-up: Recheck renal function within 1-3 months (expect temporary decline) 1
- Monitor for signs of volume depletion, especially if on aggressive diuretic therapy 1
"Sick Day" Management
Temporarily discontinue Farxiga during:
- Acute dehydrating illness (vomiting, diarrhea, fever)
- Reduced oral intake
- Major surgery (hold ≥3 days before if possible) 1, 4
- Resume when clinically stable and oral intake restored 1, 4
Special Populations
- Elderly (≥65 years): Same dosing, but higher hypotension risk - monitor BP closely 4
- Chronic kidney disease: Safe and effective down to eGFR 25 mL/min/1.73 m² 3, 1, 4
- Non-diabetic patients: Same benefits as diabetic patients 1, 7
Integration with Other HF Therapies
Farxiga is now considered foundational therapy alongside ACE inhibitors/ARBs/ARNI, beta-blockers, and mineralocorticoid receptor antagonists 1, 11. It can be started:
- Early in disease course - don't wait for maximal uptitration of other medications 1
- In addition to sacubitril/valsartan - no drug interactions 1
- During hospitalization for acute decompensated heart failure once stabilized (SBP ≥100 mm Hg, off IV inotropes ≥24 hours) 12, 2
The evidence strongly supports using Farxiga in approximately 80% of HFrEF patients in real-world practice, with the main exclusion being severe renal impairment (eGFR <25-30 mL/min/1.73 m²) 13.